When REDCap did not offer a way to use covariate-adaptive randomization algorithms (CARAs), researchers realized they would ...

MRO has appointed Lidia Bernik as president of its Curation Solutions division, strengthening the company’s leadership in ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 ...

1 School of Nursing, Henan Technical Institute, Zhengzhou, Henan, China 2 Interventional Operating Room, The Third People’s Hospital of Henan Province, Zhengzhou, Henan, China Background: Post-PCI ...

As the push to integrate artificial intelligence and increase interoperability evolves, Clinical Architecture sees a dire need for tools that can assess the quality of healthcare data. Poor quality ...

Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on ...

LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced it will present new clinical data for avigbagene parvec (FLT201), its Phase 3-ready gene therapy candidate for Gaucher ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

Japan’s Pharmaceuticals and Medical Devices Agency has traditionally been less than receptive to clinical data from other nations, but that aversion is slowly giving way. Ames Gross of Pacific Bridge ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

Lyell Immunopharma, Inc. announced that its senior management will participate in the H.C. Wainwright "HCW@Home" Series on June 25, 2025, where they will discuss promising clinical data for LYL314, ...